70 related articles for article (PubMed ID: 20573596)
21. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
23. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
24. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
[TBL] [Abstract][Full Text] [Related]
25. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment.
Ferrari AC; Stone NN; Kurek R; Mulligan E; McGregor R; Stock R; Unger P; Tunn U; Kaisary A; Droller M; Hall S; Renneberg H; Livak KJ; Gallagher RE; Mandeli J
J Clin Oncol; 2006 Jul; 24(19):3081-8. PubMed ID: 16809733
[TBL] [Abstract][Full Text] [Related]
26. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
[TBL] [Abstract][Full Text] [Related]
27. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
28. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
29. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
30. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
31. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens.
Bettuzzi S; Davalli P; Astancolle S; Carani C; Madeo B; Tampieri A; Corti A
Cancer Res; 2000 Jan; 60(1):28-34. PubMed ID: 10646846
[TBL] [Abstract][Full Text] [Related]
32. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
33. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
34. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
35. Liquid Liver Biopsy for Disease Diagnosis and Prognosis.
Tsoneva DK; Ivanov MN; Vinciguerra M
J Clin Transl Hepatol; 2023 Dec; 11(7):1520-1541. PubMed ID: 38161500
[TBL] [Abstract][Full Text] [Related]
36. Potential biomarkers for the early detection of bone metastases.
Hao Y; Zhang F; Ma Y; Luo Y; Zhang Y; Yang N; Liu M; Liu H; Li J
Front Oncol; 2023; 13():1188357. PubMed ID: 37404755
[TBL] [Abstract][Full Text] [Related]
37. Circulating Histones to Detect and Monitor the Progression of Cancer.
Tsoneva DK; Ivanov MN; Conev NV; Manev R; Stoyanov DS; Vinciguerra M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674455
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer.
Main SC; Cescon DW; Bratman SV
Cancer Drug Resist; 2022; 5(3):727-748. PubMed ID: 36176758
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic reprogramming during prostate cancer progression: A perspective from development.
Goel S; Bhatia V; Biswas T; Ateeq B
Semin Cancer Biol; 2022 Aug; 83():136-151. PubMed ID: 33545340
[TBL] [Abstract][Full Text] [Related]
40. Phenotypes from cell-free DNA.
Zukowski A; Rao S; Ramachandran S
Open Biol; 2020 Sep; 10(9):200119. PubMed ID: 32873154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
